SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is gaining traction due to its high throughput, processing millions of transactions per second, and its potential to become a compliant infrastructure solution for traditional finance. The project's interoperability with other chains and integration with a Stripe company, Bridge, are also key talking points. Community discussions revolve around Keeta's infrastructure edge and possible undervaluation compared to competitors.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

$YEE is trending as community members rally around its potential within the Ethereum ecosystem, citing a unique narrative and strong community-driven momentum. Many believe $YEE is poised for a significant breakout, drawing comparisons to past meme coin successes and highlighting its potential for substantial growth. Enthusiasts are actively encouraging others to 'study' $YEE and join the movement, emphasizing its connection to the resurgence of ETH.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs ($PL) is trending as investors digest the potential impact of its partnership with Google to build AI data centers in space, dubbed "Project Suncatcher". The community views this as a game-changer that could transform Planet Labs into a space infrastructure company, driving long-term revenue growth beyond satellite imagery. Bullish sentiment is high, with some speculating about a possible acquisition by Google and significant price appreciation.

The Coca-Cola Co. engages in the manufacturing and marketing of non-alcoholic beverages. It operates through the following segments: Europe, Middle East and Africa, Latin America, North America, Asia Pacific, Global Ventures, and Bottling Investments. The company was founded by Asa Griggs Candler on May 8, 1886 and is headquartered in Atlanta, GA.

Coca-Cola Co

Coca-Cola (KO) is trending as investors discuss a leadership transition with Henrique Braun named as the next CEO in 2026. While some view the change as unlikely to cause volatility, others are analyzing the stock's technicals, with community chatter focused on potential shakeouts and key support levels. Some traders are eyeing potential bullish reversals given oversold conditions, while others express frustration with the stock's price action and debate its premium valuation.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CRWV is trending due to a convertible note offering, sparking community debate about the company's debt and future prospects. While some investors express concern over potential dilution and financial health, others view the offering as a strategic move for long-term growth in the AI cloud sector. Discussions also revolve around CRWV's competitive positioning and potential impact from broader industry news, like Oracle's earnings.

Polestar Automotive Holding UK Plc is the Swedish electric performance car brand that engages in the research, development, marketing, commercialization, and sales of battery electric vehicles and related technology solutions. It offers Polestar 2 (PS2), a premium fast-back sedan, the Polestar 3 (PS3), a luxury aero sport-utility vehicle, the Polestar 4 (PS4), a premium sport utility vehicle, the Polestar 5 (PS5), a luxury sport grand-touring sedan, and the Polestar 6 (PS6), a luxury roadster. The company was founded on September 15, 2021 and is headquartered in Gothenburg, Sweden.

Polestar Automotive Holding UK PLC - ADR Class A

Polestar ($PSNY) is trending amid discussions of a potential reverse stock split and overall financial health, with some traders pointing out a possible short squeeze due to limited share availability and upcoming reporting this week. Despite some positive sentiment around sales numbers, the community is also discussing potential red flags on the balance sheet, high cash burn, and concerns about the stock's long-term viability within the competitive EV sector.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors anticipate earnings and potential updates on QNX technology, with the community showing increasing optimism for QNX's long-term potential in the automotive and IoT sectors. Bullish sentiment is further fueled by technical signals like golden crosses and wedge formations. Community members express growing confidence in the company's future revenue and profitability.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

MSOS is trending as investors speculate about potential rescheduling catalysts, including a possible Supreme Court decision and the potential for executive action. Community members are weighing the implications of rescheduling for US cannabis companies versus Canadian LPs, and anticipating significant gains if these catalysts materialize. Many are expressing frustration and caution due to previous false starts and disappointments in the sector.

ONDO is a DeFi primitive that enables users to originate risk-isolated, fixed yield loans backed by yield-generating crypto-assets. It's unique because it's a permissionless protocol that allows users to interact on a peer-to-pool basis with no intermediaries.

Ondo

ONDO is trending as the community discusses its potential in the tokenized real-world asset (RWA) space and upcoming catalysts. Speculation surrounds possible integrations with traditional finance, including potential partnerships with BlackRock and the launch of tokenized stocks. Some traders are closely watching a large token unlock event in January 2026.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending amid analyst downgrades and discussions around management's communication strategy following recent comments about branded checkout growth; however, some investors believe the negative sentiment is overblown and the stock is undervalued, highlighting buyback programs and potential partnerships as positives, while the community debates whether a bottom has been reached.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Shares Cross Above 50 Day Moving Average - Here's Why

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Price Pass Above 50 Day Moving Average - Time to Sell...

Wedbush on Friday raised its price target on Artiva Biotherapeutics, Inc. (ARTV) to $23 from $18 while keeping an ‘Outperform’ rating on the shares.The new price target implies a potential upside of 730% to the stock’s closing price on Thursday. Shares of the company rallied 99% on Friday at the time of writing.The price target hike <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/16/3168298/0/en/artiva-biotherapeutics-announces-refractory-rheumatoid-arthritis-as-lead-indication-upcoming-data-releases-and-corporate-update.html">follows</a> the company’s announcement on Thursday that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its cell therapy candidate AlloNK for the treatment of refractory rheumatoid arthritis in combination with Rituximab. The company also said that it has prioritized refractory rheumatoid arthritis as the lead indication for AlloNK.“Despite the many approved therapies in RA, there are over 100,000 patients in the United States who remain treatment refractory and could potentially benefit from a deep B-cell depleting therapy,” CEO Fred Aslan explained.Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects over 1.5 million people in the United States and can cause painful joint inflammation, progressive joint damage, and disability. A significant subset becomes refractory and no longer responds to or tolerates available treatment options.The company now plans to share safety and translational data for AlloNK in mid-November from patients treated with AlloNK and Rituximab across multiple autoimmune diseases, followed by clinical response data in the first half of 2026 from over 15 refractory RA patients. The CEO also added that the company is planning interactions with the FDA in the first half of 2026.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ARTV">ARTV stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:588/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_17_at_10_20_08_AM_png_e279bf0c53.webp" alt="ARTV's Sentiment Meter and Message Volume as of 10:20 a.m. ET on Oct. 17, 2025 | Source: Stocktwits" width="588" height="62"><figcaption>ARTV's Sentiment Meter and Message Volume as of 10:20 a.m. ET on Oct. 17, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the stock to rally further.<stembedurl>https://stocktwits.com/bzspy/message/632725500</stembedurl>ARTV stock is down by 45% this year and by 57% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-supervised-autonomy-analyst-warns-ahead-q3-earnings-valuation-177x-pe/ch6rM5XR3Fe">Tesla Still In ‘Supervised Autonomy,’ Says Analyst As Q3 Earnings Day Nears: ‘Shouldn’t Trade At 177x P/E’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Artiva Biotherapeutics Gets A Price Target Hike From Wedbush: Stock Rallies 99% But Retail Expects Further Rally

Wedbush’s new price target implies a whopping 730% potential upside to the stock’s closing price on Thursday.

Equity

Wedbush’s new price target implies a whopping 730% potential upside to the stock’s closing price on Thursday.


Shares of PepGen (PEPG) more than doubled on Thursday morning after multiple analysts raised their price targets on the stock following the release of positive clinical data from an early-stage study in patients with myotonic dystrophy type 1.Wedbush raised its price target on PepGen to $9 from $7 and kept an ‘Outperform’ rating on the shares, while H.C. Wainwright hiked its price target on the stock to $12 from $8.Myotonic dystrophy type 1 (DM1) is a progressive disorder that primarily affects skeletal, cardiac, and smooth muscle. It is estimated to affect about 40,000 patients in the U.S.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.pepgen.com/news-releases/news-release-details/pepgen-announces-highest-mean-splicing-correction-reported-dm1">announced</a> on Wednesday that a 53.7% mean splicing correction was observed in DM1 patients following a single 15 mg/kg dose of its PGN-EDODM1, which is higher than any previously reported splicing correction in DM1 patients. All patients who received the dose in the trial showed an improvement in splicing correction, the company noted.“Since mis-splicing is the underlying cause of DM1, we believe high levels of splicing correction have the potential to reverse the underlying molecular defects, and produce functional improvements in multiple outcome measures, including myotonia and muscle weakness, in repeat dose studies,” said Paul Streck, Executive Vice President of Research and Development at PepGen.The company previously reported mean splicing correction of 12.3% and 29.1%, respectively, with 5mg/kg and 10mg/kg doses of PGN-EDODM1.The investigational candidate was well-tolerated at a dose of 15 mg/kg, and no serious treatment-related adverse events were identified, the company stated. However, one patient had to receive oral antihistamines for treatment-related adverse events, it said.PepGen's nearly 54% correction sets a new benchmark and "strongly suggests that repeat dosing could yield clinically meaningful functional benefit," contends H.C. Wainwright.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PEPG">PEPG stock </a>rose from 'neutral' to 'extremely bullish' territory over the past 24 hours, while message volume stayed at 'extremely high' levels.&nbsp;PEPG stock is up 51% this year but down approximately 34% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/carmax-stock-tumbles-after-q2-earnings/chDlO6OR348">Why Did CarMax Stock Tumble 24% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

PepGen Stock More Than Doubles On Thursday – Check Out The New Price Targets On Wall Street

Wedbush raised its price target on PepGen to $9 from $7 and kept an ‘Outperform’ rating on the shares, while H.C. Wainwright hiked its price target on the stock to $12 from $8.

Shares of genetics research company 23andMe Holding Co, which recently filed for bankruptcy, notched its best session ever on Thursday after obtaining a legal nod to start an asset sale.Late on Wednesday, 23andMe said it had secured a U.S. bankruptcy court approval for its initial Chapter 11 motions, including wage payments, vendor compensation, and a $35-million debtor-in-possession financing agreement with JMB Capital Partners.&nbsp;The court also authorized a sale process for most of its assets, requiring buyers to adhere to 23andMe's consumer privacy policies.&nbsp;The company, working with Moelis, will solicit bids over 45 days. A second hearing on further relief, including final approval of the financing facility, is set for April 22.The news sent 23andMe's stock soaring more than 45% on Thursday, although it slid in after-hours trading.On Stocktwits, message volume about 23andMe has surged by over 26,000%, while its following has grown by 4% since the company filed for bankruptcy during the weekend.Sentiment on the platform shifted from 'bearish' to 'extremely bullish' in a day.<figure class="image"><img style="aspect-ratio:1318/302;" src="https://news.stocktwits-cdn.com/ME_sentiment_and_message_volume_as_of_March_27_png_50af800a78.webp" alt="ME sentiment and message volume as of March 27.png" width="1318" height="302"><figcaption>ME sentiment and message volume as of March 27. | source: Stocktwits</figcaption></figure>Retail investors speculated on potential buyouts, including one from co-founder Anne Wojcicki, who stepped down as CEO after the bankruptcy filing to pursue a takeover as "an independent bidder."One user estimated the company's genetic data alone could be worth over $1 billion, suggesting a buyout in the "$3-$5 range”&nbsp;per share.They also argued that even at a lowball valuation of $10 per user, the company could still be worth $100 million after debt, making it an attractive acquisition target.<stembedurl>https://stocktwits.com/SWIMHOLE/message/609440102</stembedurl>Another saw a Wojcicki buyout as unlikely and speculated that Big Pharma, international buyers, or even Chinese biotech firm BGI could become potential acquirers.<stembedurl>https://stocktwits.com/Jack_du/message/609505055</stembedurl>Retail investors also cited a media&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.thetimes.com/business-money/companies/article/british-investor-backs-rescue-of-failing-genetics-firm-23andme-swl58rsqs">report</a> about Richard Magides, the director of Singapore-based Zentree Investment and 23andMe's second-largest shareholder, expressing interest in backing a rescue effort."We believe this business is not only salvageable but could be worth over a billion dollars if the right changes are made," he reportedly said.23andMe, founded in 2006 by Wojcicki, Linda Avey, and Paul Cusenza, quickly became one of the hottest biotech startups with its DNA testing services that let users explore their ancestry and genetic traits through simple "spit kits" mailed to their homes.The company went public via a blank-check merger in 2021, at the height of the COVID-19 pandemic, reaching a peak market capitalization of $6 billion.&nbsp;However, by 2024, its valuation had plummeted to just $120 million as it struggled to churn a profit despite amassing a customer base of 15 million.Following its bankruptcy filing, 23andMe's login portal crashed Monday evening as users rushed to delete their genetic data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A view of 23andMe headquarters in Sunnyvale, California, United States on March 25, 2025. (Photo by Tayfun Coskun/Anadolu via Getty Images)

Lifeline For 23andMe? Stock Jumps After Court Greenlights Bankruptcy Asset Sale, Retail Weighs Possible Rescue Deals

Stocktwits users spotted a media report about Richard Magides, the director of Singapore-based Zentree Investment and 23andMe's second-largest shareholder, expressing interest in backing a rescue effort.

Tonix Pharmaceuticals saw its shares swing wildly between gains and losses on Wednesday morning as they started to trade following a 1-for-100 reverse stock split announced at the start of this week.&nbsp;The move aims to meet the Nasdaq's $1.00 minimum bid price requirement for continued listing.On Stocktwits, Tonix emerged as the most active biotech stock by message volume over the past 24 hours, but sentiment shifted from 'bullish' to 'neutral.'&nbsp;One popular post highlighted legal concerns, with the user accusing Tonix of manipulative practices such as "multiple RS [reverse stock splits] in a short time frame" and "lack of disclosures."A more optimistic user pointed to the Prescription Drug User Fee Act (PDUFA) goal date of Aug. 15, 2025, for FDA approval of Tonix's TNX-102 SL to treat fibromyalgia and the company's $10 million stock buyback announced in September as positive signs.<stembedurl>https://stocktwits.com/Camlandia/message/602920803</stembedurl><stembedurl>https://stocktwits.com/WARBUD/message/602912879</stembedurl>Tonix has reportedly executed multiple reverse stock splits in recent years, including in June 2024, May 2023, and May 2022, signaling a pattern of trying to maintain a minimum share price.&nbsp;The company's portfolio is focused on central nervous system disorders,&nbsp;prioritizing advancing TNX-102 SL.In December, the FDA&nbsp;<a href="https://stocktwits.com/news-articles/markets/5/tnxp-stocktwits-chatter-explodes-after-fda-nod-for-nda/cJaVYSzR1F">accepted</a> the New Drug Application (NDA) for TNX-102 SL for fibromyalgia, which is also under a separate study for acute stress reaction and acute stress disorder.Earlier in 2024, Tonix reaffirmed its commitment to developing a&nbsp;<a href="https://stocktwits.com/news-articles/markets/5/tnxp-stocktwits-chatter-explodes-after-fda-nod-for-nda/cJaVYSzR1F">mpox</a> vaccine, signaling its diversified approach to product development.Short interest in the stock has grown steadily since mid-December, rising from 0.9% to 8.5% by the end of January, according to Koyfin data.&nbsp;However, retail interest has also surged over the last three months, with Stocktwits message volume increasing by 1,750% and following jumping by nearly 10%.&nbsp;During that period, Tonix's stock price has gained more than 5%, although it has lost nearly 98% of its value over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Tonix Pharma Dominates Retail Biotech Buzz After 1-for-100 Reverse Split, Sentiment Turns Neutral Amid Volatility 

Short interest in the stock has grown steadily since mid-December, rising from 0.9% to 8.5% by the end of January, according to Koyfin data. 

Shares of NRx Pharmaceuticals Inc. surged nearly 25% on Tuesday, its best session in&nbsp;almost three weeks, drawing heavy interest from retail traders.The surge followed news of a $27 million funding deal to fund the company’s planned purchase of Hope clinics.NRx’s Hope Therapeutics unit announced a stock purchase agreement with Smith &amp; Sauer, a private investment firm specializing in healthcare and technology investments.&nbsp;The agreement includes an immediate $2 million investment in NRx common stock and a $25 million purchase of Hope’s Series A preferred shares, with $6.75 million due by Feb. 7 and the remainder by April 1.&nbsp;The funds will be used to expand Interventional Psychiatry Clinics focused on treating severe depression and other psychological disorders.Chairman Jonathan Javitt said the resources committed are expected to bring NRx to the $100 million revenue threshold.&nbsp;He added that the company had initiated a financial advisory relationship to raise an additional $400 million for broader expansion.&nbsp;"Psychedelic Medications such as ketamine, neuromodulation technologies such as TMS, and digital therapeutics have sparked a revolution in psychiatry where for the first time patients with life threatening conditions such as depression and PTSD hope for a brighter future,” he said.Retail traders on Stocktwits took note, with message volume surging 94% on Tuesday and remaining at high levels ahead of Wednesday’s market open.&nbsp;Sentiment on the stock turned ‘bullish,’ with investors speculating on the impact of the projected $100 million revenue on earnings and share price.&nbsp;One user even predicted that the stock could more than double from current levels.<stembedurl>https://stocktwits.com/jonny80s/message/601877421</stembedurl><stembedurl>https://stocktwits.com/TheRealBomb/message/601781798</stembedurl>Despite losing 11% in value over the past year, NRx Pharmaceuticals has seen a 177% gain in the past three months, driven by increasing retail interest.&nbsp;The company’s follower count on Stocktwits has risen 3% over the last 12 months, while message volume has jumped 188%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Small-Cap NRx Pharma’s Stock Draws Heavy Retail Buzz After Securing $27M Funding 

Chairman Jonathan Javitt said the resources committed are expected to bring NRx to the $100 million revenue threshold. 

BeiGene (<a class="mention" data-mention="$BGNE" data-symbol-id="BGNE" href="https://stocktwits.com/symbol/BGNE" target="_blank">$BGNE</a>) shares jumped over 5% pre-market Wednesday, with the oncology company’s stock poised to reach a two-week high after the European Commission approved its drug Tevimbra (Tislelizumab) for first-line treatment of gastric and esophageal cancers.The approval allows Tevimbra, in combination with chemotherapy, to treat esophageal squamous cell carcinoma (ESCC) and gastric or gastroesophageal junction adenocarcinoma.&nbsp;Clinical trial data showed that Tevimbra improved median overall survival to 17.2 months versus 10.6 months with chemotherapy alone, demonstrating statistically significant and clinically meaningful benefits.Mark Lanasa, Chief Medical Officer for Solid Tumors at BeiGene, emphasized Tevimbra’s role as the cornerstone of the company’s solid tumor portfolio, noting that more than 1.3 million patients worldwide have been treated with the drug.&nbsp;The latest approval adds to BeiGene’s momentum, marking six EU indications granted in just over a year.Esophageal cancer, which accounts for over 90% of esophageal squamous cell carcinoma cases, is one of the deadliest cancers. Beigene says it is projected to increase by nearly 60% to 957,000 annual cases by 2040, highlighting the urgent need for better treatment options.BeiGene has been expanding rapidly, recently reporting $1 billion in quarterly revenue, driven by U.S. and European product sales, and opening an $800 million R&amp;D and manufacturing facility in New Jersey.&nbsp;The company had also announced plans to rebrand as “BeOne Medicines Ltd.” and change its ticker to “ONC” following shareholder approval, signaling its commitment to global oncology leadership.<figure class="image"><a href="https://stocktwits.com/symbol/BGNE"><img style="aspect-ratio:1318/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/BGNE_sentiment_and_message_volume_Nov_27_premarket_749418ab8f.png" alt="BGNE sentiment and message volume Nov 27 premarket.png" width="1318" height="318"></a><figcaption>BGNE sentiment and message volume Nov 27 premarket as of 7:30 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment shifted from ‘neutral’ to ‘extremely bullish’ early on Wednesday following the approval news, accompanied by a surge in message volume.&nbsp;TD Cowen recently reiterated a ‘Buy’ rating on BeiGene and raised its price target to $260, citing the company’s robust pipeline, which it described as among the best in biotech.BeiGene stock has gained more than 8% year-to-date.For updates and corrections email newsroom[at]stocktwits[dot]com.Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/aspi-stock-slides-after-fuzzy-panda-short-call/cJIWDFNRWc">ASP Isotopes Stock Fizzles After Fuzzy Panda Short Call: Retail Eyes Opportunity</a>

Clinical trial data showed that Tevimbra improved median overall survival to 17.2 months versus 10.6 months with chemotherapy alone.

BeiGene Stock Eyes 2-Week High After EU Approves Cancer Treatment: Retail Enthusiasm Grows

The latest approval adds to BeiGene’s momentum, marking six EU indications granted in just over a year.

Current Price	$80.24
Prev Close	$80.67
Open	$80.25
Dividend Yield	N/A
50-Day Moving Average	$72.76
Beta	N/A
Avg. Volume	23,266.79
PE Ratio	N/A

52-Week High	$84.06
52-Week Low	$33.78
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

BIB
ProShares Ultra Nasdaq Biotechnology

Feed

News

Sentiment

Fundamentals

Info

Latest BIB News

BIBProShares Ultra Nasdaq Biotechnology